ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Anastrozole Better Than Tamoxifen For HR+ Postmenopausal Breast Cancer, Study Finds

May 27, 2005

Funding Opportunities: DOD releases PA On Ovarian Cancer

August 6, 1999

DCE Concepts Approved

June 27, 1986

RFA Announced On Model For Planning community Prevention Program

October 20, 1978

National Cancer Policy Forum Studies Modernization, Funding Of Cooperative Group Program.

July 11, 2008

ASCO To Open Abstracts To Everyone Prior To Annual Meeting.

November 16, 2007